RadNet (RDNT) Competitors $63.60 +1.60 (+2.58%) Closing price 08/12/2025 04:00 PM EasternExtended Trading$64.33 +0.73 (+1.15%) As of 08:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RDNT vs. HIMS, GH, OPCH, SHC, BTSG, WGS, SGRY, CON, PRVA, and VCYTShould you be buying RadNet stock or one of its competitors? The main competitors of RadNet include Hims & Hers Health (HIMS), Guardant Health (GH), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), GeneDx (WGS), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), and Veracyte (VCYT). These companies are all part of the "healthcare" industry. RadNet vs. Its Competitors Hims & Hers Health Guardant Health Option Care Health Sotera Health BrightSpring Health Services GeneDx Surgery Partners Concentra Group Holdings Parent Privia Health Group Veracyte RadNet (NASDAQ:RDNT) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings. Is RDNT or HIMS more profitable? Hims & Hers Health has a net margin of 9.63% compared to RadNet's net margin of -0.78%. Hims & Hers Health's return on equity of 26.26% beat RadNet's return on equity.Company Net Margins Return on Equity Return on Assets RadNet-0.78% 2.44% 0.84% Hims & Hers Health 9.63%26.26%13.06% Which has preferable valuation & earnings, RDNT or HIMS? Hims & Hers Health has lower revenue, but higher earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRadNet$1.83B2.61$2.79M-$0.43-147.91Hims & Hers Health$1.48B7.26$126.04M$0.8059.85 Does the media refer more to RDNT or HIMS? In the previous week, Hims & Hers Health had 63 more articles in the media than RadNet. MarketBeat recorded 83 mentions for Hims & Hers Health and 20 mentions for RadNet. RadNet's average media sentiment score of 0.80 beat Hims & Hers Health's score of 0.22 indicating that RadNet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 7 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 20 Very Positive mention(s) 5 Positive mention(s) 41 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Which has more risk and volatility, RDNT or HIMS? RadNet has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500. Do insiders and institutionals have more ownership in RDNT or HIMS? 77.9% of RadNet shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 5.6% of RadNet shares are held by insiders. Comparatively, 17.7% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend RDNT or HIMS? RadNet currently has a consensus target price of $69.60, suggesting a potential upside of 9.43%. Hims & Hers Health has a consensus target price of $39.83, suggesting a potential downside of 16.81%. Given RadNet's stronger consensus rating and higher possible upside, equities analysts plainly believe RadNet is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RadNet 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.43Hims & Hers Health 3 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92 SummaryHims & Hers Health beats RadNet on 10 of the 17 factors compared between the two stocks. Get RadNet News Delivered to You Automatically Sign up to receive the latest news and ratings for RDNT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDNT vs. The Competition Export to ExcelMetricRadNetMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.65B$3.91B$5.49B$9.68BDividend YieldN/A1.27%4.64%4.14%P/E Ratio-317.9826.3330.3825.31Price / Sales2.61149.72451.99102.74Price / Cash17.8024.7437.7258.50Price / Book4.152.798.306.01Net Income$2.79M$189.47M$3.26B$265.10M7 Day Performance20.09%13.24%1.54%1.39%1 Month Performance14.64%11.50%3.74%2.43%1 Year Performance0.54%10.95%40.92%24.74% RadNet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDNTRadNet3.1497 of 5 stars$63.60+2.6%$69.60+9.4%+3.2%$4.65B$1.83B-317.9811,021News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionHIMSHims & Hers Health2.6918 of 5 stars$49.93-3.9%$39.83-20.2%+199.8%$11.17B$2.01B62.411,637Trending NewsInsider TradeGap DownGHGuardant Health2.7253 of 5 stars$54.80+1.1%$57.50+4.9%+80.8%$6.83B$739.02M-16.362,021OPCHOption Care Health4.6633 of 5 stars$27.85-1.2%$35.75+28.4%-6.5%$4.52B$5.00B22.288,088News CoverageSHCSotera Health1.1339 of 5 stars$14.06+0.6%$16.00+13.8%+4.0%$3.99B$1.11B175.773,000Earnings ReportHigh Trading VolumeBTSGBrightSpring Health Services2.0708 of 5 stars$20.66-0.6%$25.67+24.2%+86.9%$3.66B$12.57B66.6535,000WGSGeneDx2.6827 of 5 stars$110.54+5.1%$101.63-8.1%+247.7%$3.15B$362.32M2,210.801,200SGRYSurgery Partners2.8407 of 5 stars$22.74-3.8%$33.00+45.1%-21.0%$2.92B$3.11B-15.9015,000CONConcentra Group Holdings Parent2.9086 of 5 stars$21.47-0.7%$28.50+32.7%-1.1%$2.75B$1.90B18.0411,250Earnings ReportDividend AnnouncementPRVAPrivia Health Group3.6161 of 5 stars$20.31-1.3%$28.00+37.9%+7.3%$2.48B$1.90B184.651,140News CoverageEarnings ReportAnalyst ForecastVCYTVeracyte2.6677 of 5 stars$27.99+2.3%$40.90+46.1%-3.8%$2.20B$445.76M84.82790 Related Companies and Tools Related Companies Hims & Hers Health Alternatives Guardant Health Alternatives Option Care Health Alternatives Sotera Health Alternatives BrightSpring Health Services Alternatives GeneDx Alternatives Surgery Partners Alternatives Concentra Group Holdings Parent Alternatives Privia Health Group Alternatives Veracyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDNT) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RadNet, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RadNet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access